Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ITOVEBI safely and effectively. See full prescribing information for ITOVEBI. ITOVEBI (inavolisib) tablets, for oral use Initial U.S. Approval: 2024
Medication labelWhy this: Advisory · dailymed-prescription
ITOVEBI, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy [see Clinical Studies (14.1)].
- generic_name
- inavolisib
- product_names
- Inavolisib
- ndc
- 50242-079, 50242-084, 50242-079-08, 50242-079-86, 50242-084-08
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en